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Como International Conference Position
Statement*
Lung Cancer Screening for Early Diagnosis 5 Years
After The 1998 Varese Conference
Gary M. Strauss, MD, MPH; Lorenzo Dominioni, MD; James R. Jett, MD;
Matthew Freedman, MD, MBA; and Frederic W. Grannis, Jr., MD†
Background: Lung cancer is the most common cause of cancer death in the world. Nonetheless,
public policy organizations have consistently recommended against screening for lung cancer,
with the result that screening is not widely practiced. The Como Conference was undertaken to
consider the need for a change in the existing recommendations against screening.
Purpose: The primary objective of the Como Conference was to consider whether there is
sufficient scientific evidence to advise screening for lung cancer among asymptomatic individuals
outside the context of a clinical trial. Methodological issues that are relevant to the proper
interpretation of early detection trials were carefully considered. Advantages and problems
associated with technological advances in CT scans and digital chest radiographs (CXRs) were
fully explored. Economic issues relevant to screening were also considered.
Recommendations: It is recommended that physicians assume responsibility for informing
high-risk individuals regarding options for screening for lung cancer. Targeted high-risk
individuals include middle-aged or elderly men and women who are current or former cigarette
smokers of > 20 to 30 pack-years without serious medical comorbidities. It is recommended that
such persons be informed that symptomatic lung cancer is usually advanced and incurable, while
surgery for early lung cancer offers a far better chance of cure. They should also be informed
about advances in imaging technology, as they relate to CT scans and CXRs.
Conclusions:Whenever possible, high-risk individuals should be encouraged to enroll in ongoing
trials. For subjects who, though eligible, do not have access to such trials, a process of shared
decision-making between physicians and at-risk individuals is strongly recommended. After
discussion of the existing state of knowledge, high-risk individuals should be made aware that it
is reasonable for them to choose to undergo testing for lung cancer.
(CHEST 2005; 127:1146–1151)
Key words: chest roentgenogram; cigarette smoking; computed tomography; consensus statement; early detection; lung
cancer; mortality; overdiagnosis bias; screening; survival
Abbreviations: ACS  American Cancer Society; CXR chest radiograph; NCI National Cancer Institute
T he Como International Conference on lung can-cer screening for early diagnosis was held in
Como, Italy, on November 8, 2003. The primary
objective of the Como Conference was to consider
the available evidence regarding screening for lung
cancer and to determine whether testing should be
offered to asymptomatic individuals who are at high-
risk for the disease.
Currently, lung cancer is the most common cancer
in the world. This is true both with regard to
incidence (1.2 million new cases annually represent-
*From the Division of Medical Oncology (Dr. Strauss), Brown
Medical School and Rhode Island Hospital, Providence, RI;
Center for Thoracic Surgery (Dr. Dominioni), University of
Insubria, Varese, Italy; the Division of Pulmonary Medicine (Dr.
Jett), Mayo Clinic, Rochester, MN; Imaging Science and Infor-
mation Systems Research Center (Dr. Freedman), Department
of Oncology, Georgetown University, Washington, DC; and the
Department of Thoracic Surgery (Dr. Grannis), City of Hope
National Medical Center, Duarte, CA.
†Cosponsors of the Como International Conference include
Facolta` di Medicina e Chirurgia, University of Insubria, Varese,
Italy; the Department of Medicine, Rhode Island Hospital and
Brown Medical School, Providence, RI; and the American Can-
cer Society, Atlanta, GA. This position statement, however, has
not received the endorsement of the American Cancer Society.
Manuscript received October 21, 2004; revision accepted De-
cember 14, 2004.
Reproduction of this article is prohibited without written permis-
sion from the American College of Chest Physicians (e-mail:
permissions@chestnet.org).
Correspondence to: Gary M. Strauss, MD, MPH, Division of
Medical Oncology, Rhode Island Hospital, Brown Medical
School, 593 Eddy St, Providence, RI 02903; e-mail: gstrauss@
lifespan.org
1146 Clinical Investigations
 © 2005 American College of Chest Physicians
 at Università dell' Insubria on March 8, 2012chestjournal.chestpubs.orgDownloaded from 
ing 12.3% of all cancers) and mortality (1.1 million
annual deaths or 17.8% of total cancer mortality).1
Despite the global burden of disease, the absence of
unequivocal evidence from previous randomized
controlled trials2–6 has prevented screening from
being recommended by any public policy organiza-
tion. Instead, strategies directed toward reducing
lung cancer mortality have focused almost exclu-
sively on tobacco control. Diagnostic procedures to
detect lung cancer have traditionally been recom-
mended only when symptoms develop. However, it
has long been recognized that symptomatic lung
cancer is usually advanced-stage disease. Moreover,
advanced-stage lung cancer is almost always fatal.
The 1998 Varese Conference
Five years ago, the “International Conference on
Prevention and Early Diagnosis of Lung Cancer” was
held in Varese, Italy. The proceedings of the Varese
Conference,7 which was published in 2000 and
included 34 articles, provides one of the most com-
prehensive sources of information on this subject
that has ever appeared in the medical literature.
At the completion of the Varese Conference, a
consensus statement was generated.8,9 With regard
to prevention, the statement reaffirmed the fact that
“because cigarette smoking is the vastly predominant
cause, lung cancer is almost entirely preventable.”
However, it also pointed out that “even after quit-
ting, long term smokers remain at high-risk for
prolonged periods.”
The consensus statement also recognized the
more favorable prognosis of lung cancer treated at an
early stage. For example, it asserted that among
those with lung cancer, “outcome is dramatically
better when the disease is detected at an early stage
and surgically treated. Unfortunately, at this time,
the majority of lung cancers are diagnosed when the
disease is overtly symptomatic, and in an advanced
stage when prognosis is extremely poor.”
While the consensus statement recognized the
potential of early detection to improve outcome in
lung cancer, a consensus was not reached that
screening for lung cancer should be offered outside
the context of an experimental trial. Because of
ambiguities in the data, the consensus statement
concluded that existing studies provide us “with an
imperfect basis for health policy.”
The Varese Conference helped to revitalize inter-
est in screening for lung cancer.10 Based on recom-
mendations from the Varese Conference, the Amer-
ican Cancer Society (ACS) modified its narrative
about testing for early lung cancer detection.11–13
While not recommending screening, the ACS en-
dorsed the practice that individuals who are at
high-risk for lung cancer should be informed about
their risk, and that those who seek testing for early
lung cancer detection should be informed about
options for testing for early detection, and about the
current state of knowledge on its risks, benefits, and
harms, so that they could make an informed deci-
sion. The ACS also stressed the importance of
quality control and appropriate follow-up.
The Varese Conference was an important catalytic
event that helped to reawaken interest in lung cancer
screening. It helped to establish that the existing
scientific evidence about screening was not a sound
basis for the prevailing view that lung cancer screen-
ing was ineffective. Nonetheless, although a substan-
tial body of evidence suggests that testing for early
lung cancer has the potential to reduce lung cancer
deaths,10,14 screening for lung cancer continues to be
viewed in the mainstream as experimental. Accord-
ingly, testing for the early detection of lung cancer is
not widely practiced outside the context of a clinical
trial.
Five years after the Varese Conference, the Como
Conference was held to consider whether there
existed a sufficient scientific basis to go beyond the
1998 Varese consensus statement. The particular
emphasis was on considering what might be offered
to those high-risk individuals who are not participat-
ing in an existing clinical trial.
Como Conference: Position Statement
Several studies on screening for lung cancer are
currently ongoing in many parts of the world. These
include randomized trials in the United States and
Europe,15,16 as well as the International Early Lung
Cancer Action Project.17 Whenever possible, high-
risk individuals should be strongly encouraged to
participate in available trials. It is critical that these
trials be completed in a timely manner, because they
will provide the most definitive evidence with regard
to the benefit and risks of screening for lung cancer.
Both clinicians and individuals who are at high risk
for lung cancer presently do not have specific or
consistent guidance about the balance of benefit and
harm that is associated with testing for the early
detection of lung cancer. While the results of early
randomized trials were not definitive due to known
methodological limitations, and observational studies
also have known limitations, a better prognosis and
more successful treatment have been consistently
evident when lung cancer is diagnosed and treated at
an early stage. Moreover, new imaging technologies
have been developed over the last 10 years that can
detect smaller cancers. For these reasons, it is
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reasonable that individuals who are at high risk for
lung cancer should be informed about their risk, and
what is known and unknown about the potential
benefits, limitations, and harms associated with test-
ing for early lung cancer detection.8,9,11–13
Como Conference Recommendations
Individuals who are at high risk for lung cancer
should undergo a discussion with their physician
regarding lung cancer risk and the options for testing
for the early detection of lung cancer. High-risk
individuals include men and women who are 45 to
50 years of age, who are current or former cigarette
smokers with at least 20 to 30 pack-years of cumu-
lative exposure, and who do not have life-limiting
comorbidities. Although there remain uncertainties
regarding the benefits and risks associated with lung
cancer screening, we think that it is wrong for these
discussions not to take place. It is recommended that
such discussion should include the following points:
• Smoking cessation should be strongly urged for
current smokers, and assistance for smoking ces-
sation should be provided.
• Former smokers should be informed about their
continuing risk of lung cancer.
• Whenever possible, high-risk individuals should
be strongly encouraged to participate in available
trials, or protocol-controlled observational studies.
• Individuals who are at high risk for lung cancer
should be informed that symptomatic lung cancer
is usually in an advanced stage and is usually
incurable.
• Treatment of early stage lung cancer with surgical
resection offers a better chance for a successful
outcome.
• Available methods of imaging for the early detec-
tion of lung cancer in asymptomatic subjects in-
clude the chest radiograph (CXR) and CT scan.
• There have been the following major recent ad-
vances in imaging technology: multi-slice CT scan-
ning; and energy subtraction and computer-aided
detection for CXRs.
• The available data show that the CT scan is a more
powerful imaging tool than CXR for detecting
smaller cancers. However, the CT scan also de-
tects a high rate of noncalcified nodules, most of
which are benign. While indeterminate, they
nonetheless require further evaluation. Further
evaluation includes returning for additional imag-
ing tests after 3 to 6 months or biopsy. Lung biopsy
procedures, including surgery, carry a significant
risk of complications.
• After discussion of the current state of knowledge,
it is reasonable for an individual at risk to choose
to undergo testing for lung cancer.
Medical and public health organizations should
work together to develop educational materials that
facilitate shared decision making between at-risk
individuals and their medical providers. Such mate-
rials should inform doctors and patients about the
risk of lung cancer in current and former smokers,
and, particularly, should dispel the misconception
that stopping smoking begins a process of reducing
risk to the level of a never-smoker.
Any testing for lung cancer, if it is performed,
should take place in settings with experience in the
interpretation of imaging procedures for the detec-
tion of small lung cancers, and there should be ready
access to multidisciplinary teams who work in a
coordinated manner for further evaluation and fol-
low-up.12 Efforts should be made to minimize anxi-
ety and the performance of unnecessary invasive
procedures.
Appendix
A Brief Consideration of the Evidence
The objective of this position statement is to encourage
clinicians and high-risk individuals to consider both the benefits
and risks associated with screening for lung cancer. While it does
not recommend a specific “best” screening strategy, it is intended
to convey the concept that accumulating evidence over the last 5
years supports the conclusion that screening for lung cancer,
either with a CXR or a CT scan, is a reasonable option. To
facilitate discussions between clinicians and patients, a brief
consideration of the evidence on lung cancer screening is appro-
priate.
The epidemiologic and clinical rationale for screening for lung
cancer is strong. Lung cancer is the most common and most
deadly malignancy in the world.1 When diagnosed on the basis of
signs or symptoms, lung cancer is usually incurable and lethal.
Indeed, in the United States 60% of lung cancer patients die
within 1 year of diagnosis.18 Because screening for lung cancer is
not widely practiced, the vast majority of patients are symptom-
atic at diagnosis. Accordingly, the 5-year survival rate in persons
with lung cancer is 11% worldwide and 14% in the United
States.1,19 Among patients with lung cancer, 85% will actually die
from their disease.20
In dramatic contrast, lung cancer is highly curable when
complete resection is performed for stage I non-small cell lung
cancer. Among patients with stage I disease, cure rates increase
with decreasing tumor size. For example, cure rates are 69%
when the tumor size is  1.5 cm compared to 43% when the
tumor size is  4.5 cm.21
The question of whether evidence exists from randomized
trials that screening for lung cancer is superior to no screening is
controversial. It is true that the findings of three National Cancer
Institute (NCI)-sponsored randomized trials4,22,23 in the United
States and a randomized trial from Czechoslovakia24 that was
conducted in the 1970s and 1980s have been interpreted as
indicating that CXR screening was ineffective. This is because of
a failure to demonstrate significant reductions in lung cancer
mortality in populations that were randomized to CXR screening.
On the other hand, these same trials have consistently demon-
strated significant and rather dramatic improvements in long-
term survival in experimental populations.
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In the Mayo Lung Project,25 the 5-year survival rate was more
than twofold higher in the group randomized to CXR screening
(33% vs 15%, respectively).While the Memorial Sloan-Kettering
Project26 and the Johns Hopkins Lung Project27 failed to dem-
onstrate an advantage for the addition of sputum cytology
investigation to an annual CXR alone, long-term survival was far
superior to the contemporary data.28 In the Memorial Sloan-
Kettering study,26 the 5-year survival rate was 35% in both
groups.
Screening has been interpreted as being ineffective, because
the mortality/survival discrepancy has been interpreted as indi-
cating that CXR screening led to the overdiagnosis of lung
cancer.29–33 However, this has been a point of debate. A direct
analysis of the data has suggested that the overdiagnosis was
minimal and does not account for the survival/mortality discrep-
ancies in these trials.34,35
Indeed, long-term survival was only achieved among those
persons undergoing surgical resection in these trials.35,36 In the
Mayo Lung Project,14 there were no long-term survivors among
185 lung cancer patients who did not undergo resection. In
dramatic contrast, 50% of 181 resected patients were cured.
Sobue et al37 have reported similar findings from Japan. There is,
accordingly, no direct evidence that many nonlethal or “lan-
thanic”38,39 lung cancers exist.
Furthermore, a recent analysis40 has indicated that overdiag-
nosis secondary to comorbid disease is minimal in lung cancer.
Read et al40 examined the records of 11,558 patients with lung,
breast, prostate, and colon cancers, and concluded that concur-
rent comorbidity had the greatest prognostic impact among
groups with the most favorable survival (ie, those patients with
localized prostate cancer and breast cancer) and the least impact
among groups with the poorest survival rates, which included
most patients with lung cancer.40
An important question is whether a CXR or a CT scan should
be the preferred method of screening. There is no question that
the CT scan represents a technological advance and has much
greater sensitivity than the conventional CXR. The conventional
CXR is known to be scarcely sensitive to the presence of tumors
that are  2 cm in diameter.10,41
A CT scan is clearly capable of detecting lesions than are too
small to be reliably detected on a conventional CXR. In four
nonrandomized studies,42–45 which included two in the United
States43,44 and two in Japan,42,45 52% to 85% of cancers detected
by CT scan were small stage IA lesions. In each study, many CT
scan-detected cancers were not visible on a CXR. The ability to
detect small early-stage cancers has the potential to translate into
substantial improvements in survival.
Indeed, impressively high survival was reported from the
Anti-Lung Cancer Association Project in Japan.45 Among 36 lung
cancers that were detected on initial or repeat screening, the
overall 5-year survival rate was 71% (95% confidence interval, 52
to 90%).45
However, unresolved issues remain with regard to CT scan
screening. Problems with specificity have led to a high rate of
false-positive findings in these observational studies.43–46 A
higher false-positive rate with CT scans compared to CXRs was
recently reported in the NCI-sponsored Lung Screening Study.47
In this randomized trial, which included 3,318 current or former
smokers, false-positive findings were observed in 18.6% and
9.4%, respectively, of patients in the CT scan and CXR arms.
While a CT scan is more sensitive than a CXR, the detection of
nodules on a CT scan that are not due to cancer presents
problems with regard to anxiety and the possibility of performing
unnecessary invasive procedures. In the Anti-Lung Cancer Asso-
ciation study,45 only 51% of patients (36 of 71 patients) under-
going biopsy because of nodules detected on CT scans were
found to have lung cancer. To cope with this problem, the
International Early Lung Cancer Action Project trial48 used a
protocol that was explicitly designed to minimize such operations
for benign disease. This algorithm is updated periodically based
on the total experience, and its objective is to determine what
further diagnostic studies are recommended when a small nodule
is detected on CT scan screening.48 In the Mayo spiral CT scan
screening trial,49 18% of all thoracic surgical procedures per-
formed were for benign disease.
While the evidence supports the idea that overdiagnosis was
not responsible for spurious survival advantages in older NCI-
sponsored randomized trials focusing on CXR screening,34 no
comparable evidence yet exists with regard to CT scan screen-
ing.50,51 In the Lung Screening Study,47 there were 30 cancers
detected by CT scan compared to 7 cancers detected by CXR on
baseline screening. Higher lung cancer detection rates probably
reflect the increased efficiency of CT scanning in the detection of
small lung cancers, with its associated longer lead time. However,
it is conceivable that some of the detected cancers might never
have become life-threatening during the life of the patient.
Unresolved issues with regard to false-positive findings and
overdiagnosis have implications with regard to the appropriate-
ness and cost-effectiveness of CT scan screening.49,52–54 Accord-
ingly, a definitive answer to the question of whether a CT scan is
superior to a conventional CXR must await the results of ongoing
randomized trials, particularly the National Lung Screening
Study in the United States.55
It should also be noted that technical advances have likely
improved on the effectiveness of CXRs, as employed in the older
NCI-sponsored trials. Such enhancements include digital radiog-
raphy, energy subtraction, and computer-aided detection.56
These newer CXR technologies have not been incorporated into
ongoing randomized trials, including the Prostate, Lung, Colo-
rectal and Ovarian Cancer Screening Trial57 and the National
Lung Screening Study.55
Based on the existing evidence, high-risk individuals can be
informed that if they choose to undergo screening for lung
cancer, either a CXR or a CT scan is a reasonable option. It
should be considered that in many parts of the world CT scanning
is not widely available, and in the United States it may not be
affordable by economically disadvantaged individuals. If a high-
risk individual chooses to undergo screening and CT scanning is
not available or affordable, annual CXR screening should be
recommended.
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